Compare iShares Silver Trust (SLV) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Silver Trust vs Spyre Therapeutics Inc. Common Stock — how do they compare? iShares Silver Trust trades at $51.14 (market cap $28.90B), while Spyre Therapeutics Inc. Common Stock trades at $78.35 (market cap $7.35B). The key difference: iShares Silver Trust is far larger — about 3.9× Spyre Therapeutics Inc. Common Stock's market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, iShares Silver Trust nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Silver Trust for 90 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| SLV | SYRE | |
|---|---|---|
Market Cap | $28.90B | $7.35B |
Volume | 36,248,796 | 1,624,631 |
52-Week High | $105.57 | $108.92 |
52-Week Low | $42.40 | $22.18 |
Typical Hold Time | 90 Days | 0 Days |
Sector | — | Health |
Enterprise Value | — | $6.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SLV (iShares Silver Trust) trades at $53.49, down 1.58% amid bearish technical signals with 17 sell indicators versus 1 buy. The ETF shows minimal operational activity with $0 revenue but generated $2.17M net income in 2024, supported by $13.41B in total assets against negligible liabilities. Recent news highlights silver's volatility tied to Fed policy and Treasury yields, with prices pressured by hawkish rate expectations.
Outlook remains cautious as technical weakness and macroeconomic headwinds dominate. Silver's dual role as monetary and industrial metal exposes SLV to Fed policy shifts and dollar strength, though long-term demand catalysts like central bank buying offer potential upside. Risks include sustained rate hikes and industrial demand fluctuations.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares Silver Trust
The ETF seeks to reflect such performance before payment of the ETF's expenses and liabilities. It is not actively managed. The ETF does not engage in any activities designed to obtain a profit from, or to ameliorate losses caused by, changes in the price of silver.
Read more on SLV →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
